Companies in #Urology

Neurological drug and medical device company developing “on demand” therapies that restore bowel and bladder control for people with neurological disorders.

Levee Medical is a medical device innovator focused on improving surgical outcomes for men undergoing prostate cancer surgery. Their lead product, the Voro Urologic Scaffold, is being evaluated in the ARID II pivotal trial for reducing post-prostatectomy complications.

Profound Medical Corp. is a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image-guided ablation of diseased tissue. Its lead product, TULSA-PRO, combines real-time MRI, robotically driven transurethral ultrasound and closed-loop temperature feedback to ablate physician-defined regions of the prostate, and its Sonalleve platform combines real-time MRI thermometry for the treatment of uterine fibroids, adenomyosis, palliative bone-metastasis pain and benign tumours. The company reported preliminary third-quarter 2026 revenue of $9.8–10.0 million, roughly 45–47% above analyst consensus.

R&D-driven Japanese specialty pharmaceutical company and subsidiary of Otsuka Holdings, focused on oncology, allergy and immunology and urology; developer of Lonsurf and futibatinib and parent of Taiho Oncology.

Radiopharmaceutical company developing imaging and therapeutic products for oncology, including PSMA-PET imaging agent Illuccix and the late-stage kidney cancer imaging agent TLX250-CDx; acquiring ITM Isotope Technologies Munich to add a therapeutic pipeline and isotope supply network.